Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders
Portfolio Pulse from
Levi & Korsinsky law firm has filed a securities class action lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 26, 2025 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics stock price declined after announcing discontinuation of NTLA-3001 program and potential workforce reduction, with a securities class action lawsuit filed against the company.
The lawsuit and program cancellation directly impact Intellia's stock, signaling potential financial and operational challenges that could negatively affect investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100